Language

Cardiovascular Research

Partnering with Pulse Heart Institute

For over three decades, MultiCare Health System has conducted research in the South Sound region, each year advancing a richly diverse portfolio of studies.

Now, through an exclusive partnership between Pulse Heart Institute and MultiCare Institute for Research & Innovation, we are building on 33 years of community-based-research experience and expertise in an effort to offer an even more robust cardiac research program in the Pacific Northwest. Cardiovascular studies include the following therapeutic areas:

  • Aortic and mitral valves
  • Atrial fibrillation
  • CABG coronary artery bypass grafting
  • Congestive Heart Failure
  • Hyperlipidemia
  • Myocardial infarction
  • Novel anticoagulants
  • Peripheral artery disease
  • Pulmonary arterial hypertension

Learn more about capabilities surrounding cardiovascular research.

The Principal Investigators include:

Allen Graeve, MD, FACS

Brian Kott, MD

Vinay Malhotra, MD, FACC, FAHA

Kingson Momah, MD, FACC

Dennis Nichols, MD

Jaime Pugeda, MD

Tariq Salam, MD

Needham Ward, MD, FACC

Cardiac Studies Accepting Patients

Acute Coronary Syndrome - UPSTREAM

Study Number: Utilization of Ticagrelor in the upstream setting for non-ST-segment elevation acute coronary syndrome (UPSTREAM): An ED-based clinical registry.

Study Info

Principal Investigator: Vinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301

Acute Myocardial Infarction - Paradise-MI

Study Number: CLCZ696G2301 – Prospective ARNI versus ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction.

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301

Essential Hypertension - Theracos

Study Number: THR-1442-C-603—A double-blind, placebo-controlled study to evaluate the efficacy and safety of Bexagliflozin in patients with essential hypertension not adequately controlled by Standard of Care.

Study Info - coming soon.

Principal InvestigatorAhmad Slim, MD

Study Coordinator: Dalia Sherif, [email protected], 253-403-2698 

Cardiothoracic Surgery Studies

Heart Failure

Heart Failure

Study Number: CLR325X2202 – A randomized, subject and investigator-blind, placebo-controlled study of CLR-325 in chronic stable heart failure patients.

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301


Heart Failure - AWAKE-HF

Study Number: CLCZ696BUS14 – a multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled 8-week study and 8-week open-label extension to evaluate the effect of initiation of sacubitril/valsartan on objective measure of waking activity and sleep, as health-related quality of life functions in subjects with heart failure and reduced ejection fraction. 

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301


Heart Failure - Prove-HF

Study Number: CLCZ696BUS13 – a 52-week, open-label evaluation of the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction. 

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258


Heart Failure - Emperor-Reduced EF

Study Number: 1245.121 - a phase lll randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, ion patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301


Heart Failure - Galactic HF

Study Number: 20110203 - a double blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction. 

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Tiffany Edwards, [email protected], 253-697-4192


Heart Failure - Perspective

Study Number: CLCZ696B2320 - a multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction. 

Study Info

Principal InvestigatorAhmad Slim, MD

Study Coordinator: Janey Barnhart RN, [email protected], 253-403-7258


Heart Failure - Emperor-Preserved EF

Study Number: 1245.110 - A phase lll randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253-697-1301


Heart Failure - HF Registry Study

Study Number: G-CHF - A global registry to study the demographics, socioeconomic and clinical factors, etiologies, pathophysiology, management, barriers to care, and outcomes of heart failure patients.

Study Info

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Heather McKenzie, [email protected], 253-697-4291


Heart Failure - Architect Registry Trial

Study Number: 09DY-02-16A05-01 - An evaluation of BNP Assay Cutoff in Heart Failure Population.

Principal InvestigatorVinay Malhotra, MD, FACC, FAHA

Study Coordinator: Karyna Boykin, [email protected], 253.697.1301


Heart Failure - Serenade

Study Number: AC-055G202 - A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease.

Study Info

Principal Investigator: Ahmad Slim, MD

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258

Hypercholesterolemia

R727-CL-1532

Study Number: R727-CL-1532 – a randomized, double-blind, placebo-controlled study to evaluate the effect of Praluent on neurocognitive function in patients with heterozygous familial hypercholesterolemia or with non-familial hypercholesterolemia at high and very high cardiovascular risk.

Study Info

Principal Investigator(s): Vinay Malhotra, MD, FACC, FAHA

Study Coordinator: Tiffany Edwards, [email protected], 253-697-4192

Hyperlipidemia

Esperion

Study Number: 1002-050-ole - a multicenter, Open-Label Extension (OLE) study to assess the long-term safety and efficacy of bempedoic acid (ETC-1002) 180 mg.

Study Info

Principal Investigator(s): Vinay Malhotra, MD, FACC, FAHA

Study Coordinator: Tiffany Edwards, [email protected], 253-697-4192

Mitral Valve

ON-X VALVE

Study Number: 2005-01—Clinical trial of the On-X® Valve using low dose anticoagulation.

Study Info

Principal Investigator(s)Allen Graeve, MD & Dennis Nichols, MD

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258


ON-X VALVE 17

Study Number: ON-X 2010-01—The indications for replacement of a patient’s natural or prosthetic valve will be those which the principal investigator follows in his routine practice of cardiovascular surgery.

Study Info

Principal Investigator(s)Allen Graeve, MD & Dennis Nichols, MD

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258


ON-X POST-APPROVAL REGISTRY

On-XPAS: On-X aortic prosthetic heart valve low dose warfarin post approval clinical registry study.

Study Info

Principal InvestigatorDennis Nichols, MD

Study Coordinator: Janey Barnhart, [email protected], 253-403-7258

Pulmonary Arterial Hypertension

OPUS REGISTRY

Study Number: ACC-055-503 - Multicenter, long term, real-world, observational, drug registry of
patients newly treated with OPSUMIT (macitentan).

Study Info

Principal Investigator(s): Vinay Malhotra, MD, FACC, FAHA

Study Coordinator: Tiffany Edwards, [email protected], 253-697-4192


Orpheus Registry

Study Number: AC-055-510—A multicenter, retrospective chart review of first-time Opsumit (macitentan) users in the United States.

Study Info

Principal Investigator(s): Vinay Malhotra, MD, FACC, FAHA

Study Coordinator: Tiffany Edwards, [email protected], 253-697-4192